GLP1R and acute pancreatitis: Post-marketing reports of acute pancreatitis, including both cases of necrotizing and hemorrhagic pancreatitis, associated with exenatide prompted the FDA to require a product label warning which now extends to all newly marketed GLP-1 RAs.